Lumida
/ALKS
⌘K
Alkermes Plc

Alkermes Plc

ALKS
$52.72USD↑+1.50%+0.78 today

MARKET CAP

8.8B

P/E (TTM)

49.5x

FWD P/E

—

DAY RANGE

$51 – $53

52W RANGE

$25
$56

AI Summary

Stalk
StalkMedium

ALKS remains in Stage 2 advancing within a long-term uptrend, preserving a medium-term bullish bias despite a recent pullback into key EMA support. Price is retracing into the 9/20 EMA zone on lighter volume with no exhaustion signals, offering no immediate entry trigger. We defer execution and await acceptance at the EMAs for a better entry opportunity.

  • ↑Q1 2026 net sales $338.1M (+38% YoY) driven by proprietary products
  • ↑Interim alixorexon narcolepsy trial shows sustained wakefulness improvements
  • ↓Overvalued ~64% above GF Value; negative earnings yield and low profitability
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company that focuses on developing innovative therapies for central nervous system (CNS) disorders. The company specializes in treatments for addiction, psychiatry, and sleep medicine, notably narcolepsy. The recent acquisition of Avidel Pharmaceuticals enhances Alkermes' capabilities, allowing it to enter the sleep medicine market with newly launched products like Lumerize, which positions it for growth in an underdeveloped therapeutic area.

Bull says

  • ↑Q1 2026 net sales $338.1M (+38% YoY) driven by proprietary products
  • ↑Interim alixorexon narcolepsy trial shows sustained wakefulness improvements
  • ↑Avidel acquisition boosts Lumerize sales to $72M in debut quarter
  • ↑Cash position ~$538M enables R&D funding and debt reduction
  • ↑Pipeline expansion into ADHD (ALK7290) and fatigue indications diversifies growth
  • ↑Robust liquidity and manageable leverage factors support stability

Bear says

  • ↓Overvalued ~64% above GF Value; negative earnings yield and low profitability
  • ↓Entry by Eli Lilly threatens market share and pricing power
  • ↓Integration of Avidel acquisition carries execution and cultural risks
  • ↓Q1 R&D spend $103.3M intensifies profitability pressure if revenue lags
  • ↓Reliance on payer reimbursement; adverse shifts could crimp Lumerize uptake
  • ↓Clinical enrollment delays risk pushing back key product launches

Investment themes with ALKS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026bullish

Transcript signals

Bull points

  • we had an excellent financial first quarter with another strong period of commercial execution and business performance.
  • we add a new, differentiated medicine to our portfolio, one that's early in its commercial life and has significant potential for growth.
  • From a financial standpoint, the acquisition further enhances our financial growth and provides additional resources and flexibility to advance our development portfolio.

Bear points

  • In the second quarter, we expect COGS to be in the range of $85 to $95 million, reflecting a full quarter of LUMRI sales and associated inventory step-up charge.
  • In Q1, we generated GAAP net loss of $66.5 million and EBITDA of minus $30.1 million.
Read full transcript analysis ›